Here are five points:
1. The company raised $15 million during the financing round.
2. The investment was led by Haisco Pharmaceutical Group, a Chinese pharmaceutical manufacturer.
3. The investment will be used primarily for conducting a pivotal clinical trial on Regentis Biomaterials’ GelrinC in the United States.
4. GelrinC is a proprietary hydrogel-based product. It is implanted as a liquid and is cured in-situ to form a resorbable implant.
5. It is intended for patients suffering from cartilage injuries.
More articles on devices:
Stryker buys Physio-Control for $1.28B in 3rd February 2016 acquisition: 6 key note
Medtech sells ROSA system in France: 3 things to know
Quantitative Systematic Strategies ups stake in NuVasive stock by 148.9%: 5 points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
